and Digital-to-Analog Converter (DAC) IP cores. These advanced solutions set a new benchmark for performance and efficiency, catering to diverse industries such as automotive, industrial automation, ...

and IQ digital-to-analog converter (DAC) IPs. These IPs have been silicon proven, targeted at the baseband-RF interface of LTE, WIMAX, CDMA, and WLAN communication systems for both handset and ...

And then some of them make it here. A DAC, or digital-to-analog converter, is crucial for transforming digital audio files into the analog sound we actually hear. While every digital music source ...

The AD5593R is an IO device with 8 channels that can be configured as ADC DAC or GPIO. In that sense it is one of the most flexible IO expanders on the market. The device is NOT tested with hardware ...

At the core, Agree Realty (NYSE: ADC) and Realty Income (NYSE: O) are very similar real estate investment trusts (REITs). Here's why some investors will like Agree, while others will favor Realty ...

-- Initiated dosing in Phase 1 clinical trial cohort evaluating Claudin 18.2 ADC EO-3021 in combination with ramucirumab or dostarlimab in patients with advanced gastric/gastroesophageal junction ...

Specs-wise, this little all-aluminum, baby blue and silver gadget — which also comes in a much more serious Midnight Black color — covers everything you could want in a headphone DAC ...

The latest round of federal CHIPS Act awards includes $105 million for Analog Devices to upgrade its factories in the suburbs around Portland and Boston, the Commerce Department announced early ...

MRG007 is an antibody drug conjugate (ADC), a type of therapy made by linking a toxic drug payload to a targeting antibody. Lepu has not disclosed the target of the drug, nor has ArriVent.

Written by Maria-Cristina Florian Published on January 14, 2025 The exhibition showcases a diverse range of solutions from Denmark and internationally demonstrating how urban design and planning ...

AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate (ADC) Enhertu is already making waves in breast cancer, and clinical results presented at the San Antonio Breast Cancer Symposium (SABCS ...

The drug’s Phase 3 results are comparable to those of Trodelvy, a TROP2-targeting ADC marketed by Gilead Sciences as a second-line treatment for HR positive, HER2 negative breast cancer ...